initial public offerings (IPOs) trading on American exchanges

Saturday, January 31, 2015

Spark Therapeutics (ONCE) began trading on the NASDAQ on 30 January 2015


Spark Therapeutics, Inc. is engaged in the field of gene therapy. The Company develops one-time, life-altering treatments for patients suffering from debilitating genetic diseases. The Company is focused on treating rare diseases where no, or only palliative therapies exist. The Company addresses a range of debilitating genetic diseases including inherited retinal dystrophies, hematologic disorders and neurodegenerative diseases. Its pipeline of product candidates is based on AAV vector technology. The Company’s product candidate, SPK-RPE65, is in a Phase III clinical trial for the treatment of inherited retinal dystrophies (IRDs) caused by mutations in the RPE65 gene. It is also conducting other preclinical programs such as SPK-CHM, SPK-FIX and GenableRhoNova. The Company has received both breakthrough therapy and orphan product designation for SPK-RPE65 and orphan product designation for SPK-CHM for the treatment of choroideremia.


3737 Market St Ste 1300
United States 

Key stats and ratios

Q3 (Sep '14)2013
Net profit margin--
Operating margin--
EBITD margin--
Return on average assets-33.72%-
Return on average equity--

No comments:

Post a Comment